Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

APREPITANT CRS (150 MG)

APREPITANT CRS (150 MG)

170729-80-3

DISCOVER
APREPITANT FOR SYSTEM SUITABILITY CRS (15 MG)

APREPITANT FOR SYSTEM SUITABILITY CRS (15 MG)

NA

DISCOVER
TEMOZOLOMIDE CRS (80 MG)

TEMOZOLOMIDE CRS (80 MG)

85622-93-1

DISCOVER
INDAPAMIDE IMPURITY C CRS (25MG)

INDAPAMIDE IMPURITY C CRS (25MG)

85392-00-3

DISCOVER
ENALAPRIL IMPURITY G CRS (15 MG)

ENALAPRIL IMPURITY G CRS (15 MG)

NA

DISCOVER
IRINOTECAN FOR SYSTEM SUITABILITY 1 CRS (1.5 MG)

IRINOTECAN FOR SYSTEM SUITABILITY 1 CRS (1.5 MG)

136572-09-3

DISCOVER
IRINOTECAN FOR PEAK IDENTIFICATION CRS (1.005 MG)

IRINOTECAN FOR PEAK IDENTIFICATION CRS (1.005 MG)

136572-09-3

DISCOVER
IRINOTECAN HYDROCHLORIDE TRIHYDRATE CRS (170 MG)

IRINOTECAN HYDROCHLORIDE TRIHYDRATE CRS (170 MG)

136572-09-3

DISCOVER
IRINOTECAN FOR SYSTEM SUITABILITY 2 CRS (10 MG)

IRINOTECAN FOR SYSTEM SUITABILITY 2 CRS (10 MG)

136572-09-3

DISCOVER
GASTRODIN CRS (15 MG)

GASTRODIN CRS (15 MG)

ND

DISCOVER
GENIPOSIDE CRS (15 MG)

GENIPOSIDE CRS (15 MG)

24512-63-8

DISCOVER
ISORHYNCHOPHYLLINE CRS (15 MG)

ISORHYNCHOPHYLLINE CRS (15 MG)

04/01/6859

DISCOVER